Payment overview · 2025
General Payments
$267.18
16 reported records · 6 companies
Healthcare provider profile · identity verified
R. Lamont Bloom, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WICHITA, KS · NPI 1225005879
Verified facts
What the public records show
CMS Open Payments records show R. Lamont Bloom, M.D. received $267.18 in general payments during 2025 across 16 reported records.
Amgen Inc. accounted for 60.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $162.37 | 60.8% | 10 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.14 | 11.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.88 | 7.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.42 | 6.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.58 | 6.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.79 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.18 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $162.37 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $162.37 | 10 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $31.14 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 649 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 111 |
| Montelukast Sodium | Montelukast Sodium | 475 | 128 |
| Gabapentin | Gabapentin | 377 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 87 |
| Potassium Chloride | Potassium Chloride | 328 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 320 | 86 |
| Furosemide | Furosemide | 318 | 85 |
| Omeprazole | Omeprazole | 312 | 72 |
| Prednisone | Prednisone | 311 | 153 |
| Allopurinol | Allopurinol | 298 | 72 |
| Trazodone Hcl | Trazodone Hcl | 286 | 64 |
| Lisinopril | Lisinopril | 243 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 50 |
| Sertraline Hcl | Sertraline Hcl | 223 | 54 |
| Metformin Hcl | Metformin Hcl | 208 | 57 |
| Azithromycin | Azithromycin | 205 | 135 |
| Losartan Potassium | Losartan Potassium | 205 | 47 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 200 | 53 |
| Meloxicam | Meloxicam | 191 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 47 |
| Jardiance | Empagliflozin | 179 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 51 |
| Metformin Hcl Er | Metformin Hcl | 173 | 51 |
| Eliquis | Apixaban | 171 | 30 |
| Warfarin Sodium | Warfarin Sodium | 163 | 29 |
| Tramadol Hcl | Tramadol Hcl | 159 | 39 |
| Mounjaro | Tirzepatide | 158 | 28 |
| Simvastatin | Simvastatin | 149 | 43 |
| Memantine Hcl | Memantine Hcl | 145 | 22 |
| Carvedilol | Carvedilol | 137 | 34 |
| Famotidine | Famotidine | 136 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 134 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 35 |
| Propranolol Hcl | Propranolol Hcl | 120 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 116 | 68 |
| Aripiprazole | Aripiprazole | 115 | 23 |
| Cephalexin | Cephalexin | 115 | 61 |
| Pentoxifylline | Pentoxifylline | 115 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 115 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 28 |
| Venlafaxine Hcl | Venlafaxine Hcl | 104 | 20 |
| Clonidine Hcl | Clonidine Hcl | 102 | 30 |
| Farxiga | Dapagliflozin Propanediol | 102 | 17 |
| Mirtazapine | Mirtazapine | 102 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 97 | 23 |
| Digoxin | Digoxin | 95 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 69 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 84 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 83 | 23 |
| Novolog Flexpen | Insulin Aspart | 81 | 26 |
| Amoxicillin | Amoxicillin | 76 | 46 |
| Spironolactone | Spironolactone | 76 | 19 |
| Alprazolam | Alprazolam | 72 | 13 |
| Finasteride | Finasteride | 71 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 23 |
| Trulicity | Dulaglutide | 63 | suppressed |
| Valsartan | Valsartan | 63 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 55 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Ozempic | Semaglutide | 54 | suppressed |
| Mupirocin | Mupirocin | 53 | 28 |
| Glipizide Er | Glipizide | 51 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 51 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Primidone | Primidone | 50 | suppressed |
| Fluconazole | Fluconazole | 49 | 29 |
| Ezetimibe | Ezetimibe | 48 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Cilostazol | Cilostazol | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 15 |
| Acyclovir | Acyclovir | 43 | 19 |
| Bumetanide | Bumetanide | 43 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 11 |
| Nitroglycerin | Nitroglycerin | 41 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 12 |
| Atenolol | Atenolol | 40 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 40 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 40 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 35 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 14 |
| Klor-Con M20 | Potassium Chloride | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Metolazone | Metolazone | 32 | 14 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 29 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Glyburide | Glyburide | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 18 |
| Livalo | Pitavastatin Calcium | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 19 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 14 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Clotrimazole | Clotrimazole | 23 | 14 |
| Lactulose | Lactulose | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Novolin R | Insulin Regular, Human | 21 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cartia Xt | Diltiazem Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Temazepam | Temazepam | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.18 · 16 records | Amgen Inc. | FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, LEQVIO, Leqembi, OTEZLA, REPATHA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error